|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and<3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study |
Vir: |
|
|
|
List of services to meet your request
Contains list of services for current record
|
|
|
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
|